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The advent of mesenchymal stem cell (MSC)-based therapies for clinical therapeutics has
been an exciting and new innovation for the treatment of a variety of diseases associated
with inflammation, tissue damage, and subsequent regeneration and repair. Application-
based ability to measure MSC potency and fate of the cells post-MSC therapy are the
variables that confound the use of MSCs therapeutics in human diseases. An evaluation of
MSC function and applications with attention to detail in the preparation as well as quality
control and quality assurance are only as good as the assays that are developed. In vivo
measures of efficacy and potency require an appreciation of the overall pathophysiology
of the model and standardization of outcome measures.The new concepts of how MSC’s
participate in the tissue regeneration and wound repair process and further, how this is
impacted by estimates of efficacy and potency are important new topics. In this regard,
this chapter will review some of the in vitro and in vivo assays for MSC function and activity
and their application to the clinical arena.
Keywords: adult mesenchymal stem cells, anti-inflammatory agents, antimicrobial protein, milieu therapy,
regenerative pharmacology
INTRODUCTION
Mesenchymal stem cell (MSC) developmental versatility has gen-
erated remarkable interest in their potential application in cell-
based therapy (1). The primary problematic issue in MSC-based
therapy is the variability in outcome (efficacy) and the strength
of effectiveness (potency). Once source of variability depends on
whether the cells were derived from an allogeneic (different per-
son) or autologous sources (self-derived). Autologous applications
are ideal because they eliminate issues of cross-matching, product
contamination, or potential for malignancy (2). The down-side
of autologous application is availability and the potential for self
MSC deficiencies secondary or intrinsic to the disease itself (2).
Allogeneic infusions circumvent the issue of possible ineffective-
ness but cross-reactivity and longitudinal effectiveness become the
concern. Historically, MSCs have been thought of as “immune-
privileged” with the lack of MHC II (the classical co-stimulator
molecules of the adaptive response) (3). Recently, it has been
shown that MSCs can up-regulated MHC II in inflammatory
milieus and are, indeed, recognized by the host immune system
(4). Whether this is an important component of MSC function
in vivo or not is a question and may be dependent upon the milieu
and anatomical site of action.
The fact that every MSC-donor is different (genetically, physi-
ologically, etc.) clearly becomes the most important of the uncon-
trolled aspect of both allo- and autologous MSC-based thera-
pies. Published information suggests that the secretion of pow-
erful bioactive molecules by MSCs may differ by a factor of 10
between different donors of matched age and gender (5). Thus,
potency in this context might show a high degree of variability.
The question remains as to what defines efficacy and how this
is related to the potency of the MSC and the overall desired
impact clinically of the MSCs in vivo in terms of tissue regen-
eration, wound repair, or immune-modulation. The difficulty
arises in the availability of testing MSCs for phenotypic predic-
tors in vitro, which would define the in vivo ability to function
and generate the desired effector responses. This chapter will dis-
cuss the current models for the activity of MSCs and how they
are correlated with the in vivo effectiveness of MSC function and
activity.
TISSUE REGENERATION ANDWOUND REPAIR
Mesenchymal stem cells actively respond to stress or injury in
a manner that is very similar to how the adaptive and innate
immune system cells respond to pathogen exposure or apopto-
sis. When supplied exogenously, MSCs home to sites of injury
primarily inflamed or broken blood vessels. There is an intri-
cate array of soluble mediators generated by MSCs in a milieu
specific manner, almost “sensing” the requirement of the environ-
ment. These products can promote angiogenesis, regeneration,
remodeling, immune cell activation or suppression, and cellu-
lar recruitment. At the same time the MSCs can also actively
participate in bactericidal activity. MSCs are perivascular cells,
pericytes, and as such, they will not respond the same given
that the microenvironments of different tissues are not the same,
this will also impact efficacy and/or potency. The functionality
of the MSC preparation is based upon isolation and expan-
sion procedures and the injury-specific environment that they
find themselves in. The ability MSCs to respond to the given
environment is attributed to the ability of them to respond to
changes or requirements of the milieu through transcriptional
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regulation and translation of appropriate responding mediators.
This responsiveness is due to receptor recognition and signal
transduction followed by the release of specific protein media-
tors that influence the milieu for repair, control of inflammation
and infection. The repair process entails regulating extracellu-
lar matrix deposition, collagen synthesis, fibroblast proliferation,
platelet activation, fibrinolysis, and angiogenesis. The immune
process often involves suppressing T-cells, activating macrophages,
and potentially recruiting neutrophils. Studies have also suggested
that immune regulation by the MSCs is defined by the soluble
products generated by the MSCs facilitating changes in immune
cell activation status. The products produced by the MSCs are
not different from those of the immune system and can include
cytokines, inflammatory mediators, and antimicrobial proteins.
Table 1 lists some of these products and references of production
and action.
EFFICACY
What is efficacy? Efficacy as defined as “the power to produce
an effect” (6). The “effect” in the context of MSC biology is
whether the end-point is reconstruction, regeneration, repair,
anti-inflammatory, anti-autoimmunity, or any other hypothesized
clinical applications for the use of MSCs clinically. To further
complicate the notion of MSC efficacy is the focal point of dif-
ferentiation and desired function of the MSCs. There is also a
distinction between the efficacy of cell–cell impact and the efficacy
of soluble products generated by MSCs. The required numbers of
infusions of MSCs may also confound efficacy. In a study eval-
uating graft versus host disease (GvHD), it was found that in
some of the patients, several infusions were required to sustain
the positive outcome (7, 8). This does not imply that all of the
GvHD subjects responded in a positive manner to the MSC load,
some did not which begs the question of potency. Is the fact
that some patients require more dosages than others due to the
potency or “strength of the MSC preparation” and is the “strength
of the MSC preparation” also defined by the degree of injury or
illness and the general health and age of the recipient? These are
all very difficult matters to control in the context of clinical tri-
als and may have a major role in some of the complexity of the
outcomes in MSC-based clinical trial applications. Figure 1 show
efficacy being defined by a variety of factors which are not only
associated with the MSCs themselves but also the host involve-
ment in defining the ultimate residence and milieu for MSC
effectiveness (9, 10).
POTENCY
Potency, or the ability or capacity to achieve or bring about a par-
ticular result, is a major component which defines the ultimate
efficacy or the power to achieve a particular event (11). The differ-
ence between these two terms, potency and efficacy, lies in the
generalized capacity to be impactful (potency) and with what
intensity is this impact instituted (efficacy). MSCs must first have
the capacity to achieve the desired effect, which then is followed by
how much and how long MSCs need to be in the desired context
to institute the response. The question also begs the issue of what
is the desired response? In the asthma studies, when MSCs are
infused in the absence of inflammation, the tendency is to have
a greater cellular recruitment into the lung (suggesting a xeno-
graphic response) (6, 12). However, when the hMSCs are given
in the context of airway disease (both allergen challenge or infec-
tion), they then become immunosuppressive reversing the cellular
recruitment, which is generally seen in response to the pulmonary
insult. In these studies, the hMSCs were given intravenously at 106
cells/mouse post-challenge. The difference between these obser-
vations has to do with the localization of inflammation and injury
in the context of allergen challenge. These studies further showed
that the MSCs are potent in the context of pre-existing airway
disease. Similarly, the intensity by which the MSCs induced the
response is shown by the variability of the change in lung differen-
tial between study sets. The investigators in these studies further
define this variability based upon the separately assayed ability
of the MSCs to induce bone formation in an in vivo implan-
tation efficacy assay. These studies showed that the assay for
bone formation mirrored the in vivo decrease in cellular recruit-
ment even in the context of allergen challenge. The connection
between bone formation and lung efficacy is not obvious to us and
likely somehow reflects the functionality of MSCs in two different
microenvironments.
Table 1 | Mesenchymal stromal cells and paracrine factors of inflammation.
Mediator Function Reference
TNFα stimulated gene 6 (TSG-6) Binds hyaluronan, inhibits inflammatory functions (58, 59)
IL-1RA Blocks IL-1α and IL-1β function in macrophage activation, T-cell recruitment (60–62)
PGE2 T-cell suppression, decrease IL-10 production. Suppresses IL-17 production (63–65)
Indoleamine 2,3-dioxygenase T-cell suppressor (66–68)
Nitric oxide Pro-versus, anti-inflammatory, macrophage regulator. T-cell suppressor (69–71)
TGFβ1 Suppress T-cell activation, macrophage activation. Inhibits dendritic cell migration (72–74)
SDF-1 (stromal cell derived factor) Stem cell progenitor cell recruitment, tissue regeneration (75–78)
VEGF, EGF, IGF-1 Anti-apoptosis, differentiation, and angiogenesis (79–81)
LL-37 Antimicrobial and anti-inflammatory functions (38, 82)
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FIGURE 1 |The dynamic definition of MSC efficacy. Efficacy or the
biological impact of MSC on biological processes is dependent on a variety
of parameter. As outlined in the schematic below the variability in efficacy is
dependent not only on the source and quality of the MSCs themselves but
also on the response of the recipient to the administration of MSCs. This is
a dynamic and continuous process that can ultimately be defined by the
potency of the MSCs in the context of disease, model, and outcome
measure.
MEASURES OF EFFICACY
Traditional measures of efficacy have been done in vitro using
very tightly controlled environments in terms of medium, fetal
calf serum (FCS), supplements, and buffering systems (12, 13).
In some cases, the specific serum lots are essential for the optimal
biologic response of the model system. The idea behind the in vitro
modeling is the ability to take the multipotent MSCs and treat
them with the conditions for effective differentiation. The end-
point activation or differentiation is then tightly controlled for
validation of the multipotent differentiation process. The issues
of pre-phenotype before differentiation and post-phenotype after
differentiation can be different from one laboratory to another,
which confounds the terms of “efficacy” when referring to MSCs.
Keep in mind that as pericytes in vivo, MSCs function in response
to injury. This is quite different and separate from their capacity
to differentiate into bone, cartilage or other surrounding tissues in
an in vitro culture environment. Commercialization would require
these processes of activation or differentiation to be standardized
so that preparations could be compared across institutions and
continents. Further, the in vitro scenario which is chosen is often
the one used in the context of the application being studied. It
would be useful to probe the question as to the differences in
the differentiation potential of hMSCs in the context of a specific
application of choice. For example, if the application is for asthma,
would it be appropriate to use the in vitro chondrocyte differenti-
ation process as well as adipocyte differentiation to define in vitro
efficacy and how this correlates to the observations in vivo? These
in vitro models for identifying the capacity for MSCs multi-lineage
differentiation use different differentiation conditions to achieve
chondrocytes, adipocytes, and osteoblasts (2, 13, 14). Alternatively,
studies have also focused on the functional ability of the MSCs to
induce an effect such as suppression of T-cell activity and cytokine
production (15, 16).
DIFFERENTIATION EFFICACY
Mesenchymal stem cells, regardless of where they are isolated from,
can be induced to differentiate in vitro in an effort to define
efficacy. As stated, efficacy is defined by the end-point differen-
tiated product, which by its nature is defined by the conditions of
differentiation (17). There is no quantitative way in which MSCs
can be defined from the beginning as to their ability to differenti-
ate into either one of the following types of end-point phenotypes.
To complicate things further, just because a cell is pushed into a
specific direction of differentiation, it appears that they have the
capacity to be redirected. For example, an epidermal skin cell can
be pushed into another type of cell completely depending upon
the conditions of culture. The basis for the ability to differenti-
ate and to re-direct to accommodate the milieu or teleological
“sensing” of required response is based upon the identification
or the originating cellular source of the MSC. MSCs are thought
to be derived from pericytes (18). Pericytes are perivascular cells
with multifunctional activities which are just now being eluci-
dated. The functional interaction of pericytes with the endothelial
cells is thought to be the source for differentiation and definition
of MSC differentiation (19). Injury results in vascular changes
even at the micro-vascular level. These changes stimulate peri-
cyte differentiation into targeted MSCs that hone to the injury
and repair perturbed tissue as well as modulate the surround-
ing in vivo environment. As pericytes are multipotent their ability
to define MSCs targeted function is outlined in Figure 2. The
environment of culture in vivo ultimately defines the process of
differentiation and end-point tissue. Variations of the tissue dif-
ferentiation will depend on the quality and the quantity of specific
inducers of the differentiation process. The traditional measures
of MSC differentiation post-transition from the pericyte include
the following.
Chondrocytes
For chondrocyte differentiation, MSCs are put into spheroids by
centrifugation and incubation in chondrogenic-specific induction
medium using a chemically defined medium of DMEM containing
specific lots of FCS and transforming growth factor beta (TGF-β)
for 25 days (20–22). To define the success of chondrocyte devel-
opment, the spheroids are fixed in 10% buffered formalin for 2 h
at room temperature followed by dehydration with xylene and
paraffin. Paraffin sections then are stained with 0.1% Safranin
O to detect mucopolysaccharide synthesis indicative of chondro-
cyte production. An alternative to the histology, some investigators
use quantification of glycosaminoglycans (GAG) to determine
differentiation potential.
Adipocytes
For adipocyte differentiation, MSCs are cultured in a defined
medium including FCS, dexamethasone, ascorbic acid, and 1-
methl-3-isobutyl-xanthine. Growth occurs for at least 14 days
followed by Oil-Red O staining to show adipocyte differentia-
tion (23, 24).
Bone
For osteoblastic differentiation, MSCs are cultured in DMEM sup-
plemented with 10% FBS, β-glycerophosphate, dexamethasone,
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FIGURE 2 |The mesengenic process. Mesenchymal stem cells are multipotent and possess the ability to proliferate and commit to different cell types based
on the environmental conditions. They also may be redirected from one lineage to another.
and ascorbic acid. After 21 days, the cells can be stained with
van Kossa’s stain to reveal osteogenic differentiation or chemically
analyzed for calcium accumulation (25–27).
FUNCTIONAL EFFICACY
A variety of functional assays can also be used to measure MSC
efficacy. The point of these assays is to measure the ability of the
MSCs to induce a specific effect. MSCs have been shown to have an
immunosuppressive effect on T-cells (15) both as an activity and
also in their ability to produce lymphokines (28). Traditional T-cell
proliferation assays using the incorporation of tritiated thymidine
3 days post stimulation in the presence of antigen presenting cells
with and without MSCs can be an easy 3-day assay for MSC effi-
cacy. These studies can be further simplified by using one of the
newer assays that involve using T-cell ATP levels as an indicator
of activity (29). In these studies, no radiolabel is required and
the assay is a direct 18-h output. T-cell cytotoxic cells can also
be used as indicators of MSC efficacy for the same purpose as
the T-cell activity assay (30, 31). The interesting issue is the dif-
ferences between the assays in terms of MSCs effector function:
the MSC preparation which suppresses the T-cell proliferative
responses may not be as effective at attenuating the ability of T-cells
to mediate a cytotoxic response.
IN VIVO VERSUS IN VITRO MODELS
Several in vivo experimental studies have shown the value of allo-
geneic or xenogenic MSCs for a variety of disorders including:
sepsis, hepatic failure, acute renal failure, and myocardial infarc-
tion (32). The issue with in vivo models of efficacy has to do with
the validity of the model itself and the inherent variability that
exists with in vivo experimentation. The other issue that needs to
be addressed is the assessment of efficacy and the duration required
to obtain that outcomes. In vivo models are more expensive and
are inherently more time consuming with the issue of translation
to human applications a major focus. The choice of model, dura-
tion of MSC exposure, dosing required to induce the effect, and
final outcome can be interpreted as strong indicators of the abil-
ity to use MSCs in vivo. Interestingly there have been a variety of
studies in which xenographic hMSCs have been utilized in animal
models that show similar effectiveness to allogenic and autolo-
gous MSCs (6, 12). In acute renal failure in mice, intravenous
MSC therapy hastened renal tubular epithelial cell recovery (4),
and markedly improved mortality from peritoneal sepsis in mice
regardless of whether the MSCs were allogeneic or autologous
(33). For example, the documented studies involving lung inflam-
mation, administration of MSCs was post-injury suggesting the
injury requirement in the function (recruitment or activation)
of the MSCs to the interface of lung injury. These studies would
provide in vivo models of efficacy and would define the potential
for different “efficacy” and “potency” directives depending on the
injury itself. A few examples of specific models will be discussed.
LUPUS
Mesenchymal stem cells have been shown to have a profound
impact on the impact of disease progression in the murine model
of lupus (34). Murine lupus can be induced in 6- to 7-week-
old female C57BL6 mice by immunization with an emulsion
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containing 300µg of purified myelin oligodendrocyte glycopro-
tein (MOG) and an equal volume of complete Freund adjuvant
followed by intra-peritoneal injections with Bordetella pertussis.
Animals are scored daily for neurological symptoms according
to the murine lupus clinical severity scale: 0= asymptomatic;
1= partial loss of tail tonicity; 2= tail paralysis; 3= hind limb
weakness; 4= hind limb paralysis; 5= limb paralysis; 6= death.
MSCs have been given intravenously at 106 MSCs/100µL (using
saline as the vehicle control). Changes in the scoring of the MSC-
treated mice can then be used as a measure of efficacy. For potency,
the same model can be used comparing single dosing versus
multiple dosing for selected time points (35, 36).
SEPSIS
Mesenchymal stem cells have been shown to be effective at improv-
ing survival of mice in the sepsis model (37). Sepsis can be induced
in C57Bl/6J mice by cecal ligation and puncture, followed 6 h later
by an intravenous injection of MSCs or saline. Bronchoalveolar
lavage (BAL) fluid and tissues can be collected for analyses at 24 h
post infection. MSC treatment has been shown to significantly
reduced mortality in septic mice receiving appropriate antimi-
crobial therapy which included reduced systemic and pulmonary
cytokine levels in mice with induced sepsis, preventing acute lung
injury and organ dysfunction (38).
ACUTE LUNG INJURY
In this model, mice are given and intratracheal instillation of
lipopolysaccharide with and without MSC (39). Total cell count,
cytokines associated with the lung injury, and other pathophys-
iological data can be assessed and correlated with MSC impact
on LPS-induced lung injury. This model would be relative to the
MSCs ability to react versus host response and bacterial burden.
The advantage of this model is that it is fast, and reproducible. The
disadvantage is that it focuses on only the trophic components of
MSCs efficacy (37).
ACUTE ASTHMA
This is an immunological model and would be used to define
the suppressive effects of the hMSCs (40). In these studies, Balb/c
mice can be sensitized by intra-peritoneal injections of ovalbumin
(OVA) emulsified in Al(OH)3. After 14 days are then exposed to
1% weight/volume OVA in sterile saline by aerosolization every
day for 5 days (12). hMSCs are given on either day 14 or day
16 by tail vein injection with 1× 106 hMSC/mouse in 100µL of
PBS. As a positive control for immunosuppression, a subset of the
OVA sensitized, OVA challenged mice received dexamethasone at
10 mg/kg. The dexamethasone can significantly decrease total cell
recruitment and eosinophil counts and can be used for a control
of immunosuppression.
MULTIPLE SCLEROSIS
In the autoimmune model of multiple sclerosis (MS), mice are
injected with myelin protein to induce experimental autoimmune
encephalitis EAE (34). The animals mimic many of the patho-
physiological processes associated with MS development and pro-
gression. Infusion of MSCs in the EAE model of MS significantly
improved survival and decreased markers of inflammation asso-
ciated with specific outcome of disease (41). The resolution of
EAE definable markers of pathology can be a powerful tool for
measuring in vivo efficacy and potency of MSCs.
There are other suggested in vivo models such as hepatic failure,
kidney failure, and myocardial infarction but these require more
time, are even more expensive, and at the end, probably do not
provide any more detail than the short term in vivo efficacy assay
described above accept for the end-point evaluation of investiga-
tion (42, 43). Depending on the perspective, a focused approach
to the type of outcome desired and the criteria of that selection
may be important in choosing any of these models whether they
are simple or complicated.
EX VIVO
With the significance in translating between the observations of
in vivo modeling and in vitro modeling in hMSC therapeutics,
some groups have been able to develop ex vivo models using per-
fused tissue from humans post-surgery. Matthay and co-workers
adapted an ex vivo perfused human lung preparation for studies
of acute lung injury to test the effects of MSC therapy (39). In
this study, the right middle lobe was injured with intra-alveolar
endotoxin, resulting in a sharp increase in lung endothelial and
epithelial permeability to protein leading to pulmonary edema and
loss of the normal capacity of the alveolar epithelium to remove
alveolar fluid. When the lung was treated 1 h after instillation
of the endotoxin with intra-bronchial allogeneic MSC, the lung
vascular permeability and extra-vascular lung water returned to
normal levels. These studies also used culture medium generated
from MSCs induced the same effect suggesting the impact was
based upon soluble response of the MSC to the lung milieu. Inter-
estingly, investigators using the EAE model also showed that the
impact of MSC on EAE pathophysiology was mediated through
products generated by the MSCs themselves in response to the
inflammation (44).
CONUNDRUM OF CONTROLS IN VIVO MSC RESPONSE
One issue that is often brought up is the issue of cellular specificity
in terms of response to MSCs. What is the appropriate control of
MSCs administration in vivo? The control would need to repre-
sent the species of origin and phenotypic presentation. This is a
major issue since in many studies the MSCs are of human origin
and are not autologous. These are xenographic and cross-species
studies. Although, the MSCs are thought to be immune-privileged,
the cross-species is a good control for the species effect. In other
situations, non-MSC-based cells are used as controls such as fetal
fibroblasts or bone marrow-derived differentiated cells or fibrob-
lasts. These might be derived from the same species, but they
will not have the same phenotypic presentation since it is likely
that they will have MHC class II and maybe even MHC class I
expression.
DELIVERY, TIMING, AND SOURCES OF MSC THERAPY
ROUTE OF DELIVERY
The optimal route of delivery for the MSC is unknown (44, 45).
Would intravenous delivery of MSCs result in the same benefit as
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direct tissue delivery? The main point is whether the MSCs have
the capacity to home or to direct “themselves” to injured organs
and whether the injury occurs in the liver, kidney, or the lung.
The other possible context is that it is the homing issue as it is
in the accessibility of the injury sites to the vasculature and the
“pericyte” nature of the MSCs themselves. Systemic administra-
tion allows for the process of journey and differentiation, but may
impact the ultimate efficacy and potency of the MSC preparation.
The benefit of direct tissue administration is the milieu effect and
optimization of the MSC preparation.
DOSING AND TIMING OF TREATMENT
The dosing and timing of MSC treatment is also an issue that
still needs to be addressed and confirmed for translational appli-
cations. In the context of a specific disease entity, dosing may be
defined by the potency, efficacy of the MSC preparation, and the
status and phenotype of the disease. In the in vivo asthma studies,
a single dosing of MSC was used and showed significant impact on
the murine model of both acute and chronic disease (6, 12). This
is the same for the other in vivo models (34, 46, 47). Interestingly
in clinical trials of MSCs in Crohns disease, osteogenesis imper-
fecta, MS, and acute steroid-refractory GvHD, multiple infusions
were required to sustain or induce the clinical improvement (17,
48). In these clinical studies, the definition of who received mul-
tiple dosages, why they received multiple dosages, and were these
from the same batch of MSCs of different donors is an issue. This
makes understanding the biological components and success of
the studies difficult. Since some patients required more infusions
than others, suggests and efficacy and potency effect. Future stud-
ies need to better control for the efficacy and potency within the
clinical trial using both in vivo and in vitro assessments of activity.
This would be a costly endeavor but essential as studies translate
into the application to human disease and the cost of each MSC
preparation.
TARGETING BLOOD BORE MSCs
With the notion that pericytes are stimulated to define MSC
function and homing properties, the obvious application is pro-
viding targeting for directed MSC function in vivo (49, 50). For
example, studies have used genetically engineered MSCs using ex
vivo retroviral transduction to overexpress the pro-survival gene
Akt1 (encoding the Akt protein which is important for survival)
to improve overall survival of MSCs in vivo (51). Transplanta-
tion of MSCs overexpressing Akt into ischemic rat myocardium
inhibited the process of cardiac remodeling by reducing intramy-
ocardial inflammation, collagen deposition, and cardiac myocyte
hypertrophy. MSCs transduced with Akt1 restored fourfold greater
myocardial volume than equal numbers of cells transduced with
the control reporter gene. These observed effects were dose (cell
number) dependent. Thus, MSCs genetically enhanced with Akt1
can repair infarcted myocardium, prevent remodeling, and nearly
normalize cardiac performance. Other studies have started to focus
on the use of targeted MSC in other diseases. In one set of studies,
an adeno-associated virus vector was used to disrupt dominant-
negative mutant COL1A1 collagen genes in MSCs from individuals
with the brittle bone disorder osteogenesis imperfecta (52). These
studies demonstrated that the concept of MSC correction (53)
and potential for directed gene therapy can be successful in human
stem cells providing exciting potential for therapeutic applications.
Further, in recent studies, glyco-engineering of hematopoietic cell
E-/L-selectin ligand (HCELL) on MSCs can target hMSCs to
marrow, licensing transendothelial migration without chemokine
signaling via a VLA-4/VCAM-dependent pathway (54, 55). This
homing receptor concept also has the potential of introducing
new ways of specifically targeting cell-based therapy to disease
sites.
SOURCES OF MSCs
Mesenchymal stem cells can be extracted from several sources
within the body and their usefulness in different disease processes
may depend on their source. Examples of sources include adipose
and synovial tissue, peripheral blood, skeletal muscle, umbilical
cord blood, placenta, and bone marrow. The procedure for obtain-
ing MSCs from donors can be relatively invasive (i.e., bone marrow
aspiration) or minimally invasive (i.e., liposuction). Although
MSCs obtained from different regions of the body show simi-
lar potential for differentiation and therapeutic effects, they each
express different cellular markers. For example, adipose-derived
MSCs express higher levels of CD49d, CD34, and CD54 whereas
bone marrow-derived MSCs have higher levels of CD106 (56, 57).
The clinical and therapeutic significance of these markers remains
to be elucidated, however. Also, the differentiation potential of
MSCs may vary from source to source, and number of actual cells
obtained from each source may vary based on their source, age of
the donor, and co-morbid conditions. More in depth studies are
needed to determine if certain MSC sources are more beneficial
in certain diseases and if their therapeutic effectiveness and safety
profiles are similar.
CONCLUSION
Mesenchymal stem cells have become a major focus for a potential
resource in therapeutic cell-based therapies. MSCs are multipo-
tent cells derived from stromal tissue, which have the capacity
to differentiate into mesodermal and endodermal types of cells.
Not only do MSCs have the capacity to differentiate into dif-
ferent types of cells depending on the tissue matrix, they also
actively contribute to their milieu by secreting soluble prod-
ucts that actively participate in MSC and surrounding cell phe-
notype. The issues related to therapeutically translating MSCs
into the clinical arena are based upon the ability to predict
the host response, the intensity of the response, and the dura-
tion of the response. These parameters are associated with the
potency and efficacy of the stem cell preparation. In vitro and
ex vivo assays are available to define the relative efficacy of sev-
eral in vitro and in vivo assays which can ultimately be used
to define MSC efficacy and potency, but these are going to
be tissue-specific and disease-specific. In the end, correlating a
specific type of disease process (inflammation versus remodel-
ing) must be used to define the activity of the MSCs. This will
become especially true as new sources besides bone marrow-
derived MCSs become clinically available and are approved for
clinical applications.
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